Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric citrate - Akebia Therapeutics

Drug Profile

Ferric citrate - Akebia Therapeutics

Alternative Names: Auryxia; AVA-1014; Ferric citrate dihydrate; Ferric citrate hydrate; Fexeric; JTT-751; KRX-0502; Nephoxil; PBF-1681; Riona; Tetraferric tricitrate decahydrate; Zerenex

Latest Information Update: 26 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacor Bioscience; Panion & BF Biotech
  • Developer Akebia Therapeutics; Averoa; Japan Tobacco; Panion & BF Biotech; Torii Pharmaceutical
  • Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids; Urologics
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia; Iron deficiency anaemia
  • Preregistration Kidney disorders

Most Recent Events

  • 23 Apr 2024 Preregistration for Kidney disorders in European Union (PO)
  • 23 Apr 2024 Averoa expects a review of accepted MAA application under the centralised marketing authorisation procedure and a decision on a potential approval in 2025
  • 31 Dec 2023 Akebia Therapeutics has patent protection for Ferric citrate in US and worldwide excluding certain Asian-Pacific countries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top